Associated Papers
Contemporary Management of Familial and Multifactorial Chylomicronemia Syndromes in Italy: Insights From the National LIPIGEN Registry.
D'Erasmo L et al.
Arteriosclerosis, Thrombosis, and Vascular Biology, 2025
41099101 (PubMed )
Supplement: atv-45-2264-s001.pdf
Monogenic hypertriglyceridemia and recurrent pancreatitis in a homozygous carrier of a rare APOA5 mutation: a case report.
Makhmudova U et al.
Journal of Medical Case Reports, 2024
Biochemical, Clinical, and Genetic Characteristics of Mexican Patients with Primary Hypertriglyceridemia, Including the First Case of Hyperchylomicronemia Syndrome Due to GPIHBP1 Deficiency.
Rodríguez-Gutiérrez PG et al.
International Journal of Molecular Sciences, 2022
Apolipoprotein A5: Extracellular and Intracellular Roles in Triglyceride Metabolism.
Forte TM et al.
Current Drug Targets, 2015
Apolipoprotein A-V; a potent triglyceride reducer.
Nilsson SK et al.
Atherosclerosis, 2011
Apoprotein A-V: an important regulator of triglyceride metabolism.
Kluger M et al.
Journal of Inherited Metabolic Disease, 2008
Rare APOA5 mutations--clinical consequences, metabolic and functional effects: an ENID review.
Talmud PJ
Atherosclerosis, 2007
APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency.
Calandra S et al.
Current Opinion in Lipidology, 2006
Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?
Jakel H et al.
Annals of Medicine, 2006
Determination of the functionality of common APOA5 polymorphisms.
Talmud PJ et al.
The Journal of Biological Chemistry, 2005
Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia.
Priore Oliva C et al.
Arteriosclerosis, Thrombosis, and Vascular Biology, 2005
Variability of longitudinal triglyceride phenotype in patients heterozygous for pathogenic APOA5 variants.
Perera SD et al.
Journal of Clinical Lipidology, 0
Select a paper to view details